The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Should there be a moratorium on the use of cholesterol lowering drugs?
Open accessAbstract
Recent reviews of the primary prevention of coronary heart disease through lowering cholesterol concen- trations have varied considerably in their evaluation of the benefits of the intervention.[1][2][3][4] The degree of disagreement is surprising as they review essentially the same data, from clinical trials of cholesterol lowering by drugs or by diet.There is agreement about a reduced risk for coronary events, but there are differing interpretations of the increase in mortality from non-cardiovascular causes that has generally been seen.Particular concern was generated by a recent meta-analysis that showed a significantly increased risk of death from accidents and violence when the results of six randomised primary prevention trials were pooled.3Despite the uncertainty an aggressive approach to cholesterol reduction features in most of the official guidelines for the primary prevention of coronary heart disease.`InBritain the introduction of the new general practitioner contract, with its focus on health promotion, is likely to result in an increase in cholesterol testing.High percentages of the British population would become candidates for drug treat- ment if the guidelines currently advanced by some authorities were put into practice.For middle aged men and women with other coronary risk factors the European Atherosclerosis Society recommends a cut off level, above which the use of lipid lowering drugs should be considered,6 well below the mean population cholesterol concentration.0`'2The entry criteria for the expanded clinical evaluation of lovastatin study (EXCEL)"5 would include a third of the British population.[10][11][12]
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
Goodman, D. S. (1988) · Archives of Internal Medicine · doi:10.1001/archinte.1988.00380010040006 · Cited by 2,246
Muldoon, M. F., Manuck, S. B., & Matthews, K. A. (1990) · BMJ · doi:10.1136/bmj.301.6747.309 · Cited by 960
Lowering Blood Cholesterol to Prevent Heart Disease
(1985) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1985.03350380096029 · Cited by 663
Lowering blood cholesterol to prevent heart disease
Hupp, J. R. (1985) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/0278-2391(85)90208-3 · Cited by 644
DAYTON, S., PEARCE, M. L., HASHIMOTO, S., DIXON, W. J., & TOMIYASU, U. (1969) · Circulation · doi:10.1161/01.cir.40.1s2.ii-1 · Cited by 595
EFFECT OF CHOLESTEROL-LOWERING DIET ON MORTALITY FROM CORONARY HEART-DISEASE AND OTHER CAUSES
Miettinen, M., Karvonen, M., Turpeinen, O., Elosuo, R., & Paavilainen, E. (1972) · The Lancet · doi:10.1016/s0140-6736(72)92208-8 · Cited by 497
A comparison of statistical methods for combining event rates from clinical trials
Berlin, J. A., Laird, N. M., Sacks, H. S., & Chalmers, T. C. (1989) · Statistics in Medicine · doi:10.1002/sim.4780080202 · Cited by 420
Cited by
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
PEDERSEN, T. R. (2004) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2004.08.027 · Cited by 3,106
Metadata
- Authors
- Davey Smith, G., & Pekkanen, J.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 1992-02-15
- Volume
- 304
- Issue
- 6824
- Pages
- 431-434
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W2085709114
- Cited by
- 333
- References
- 40
- FWCI
- 66.38
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Should there be a moratorium on the use of cholesterol lowering drugs? https://app.cochat.ai/papers/10.1136/bmj.304.6824.431
- The paper
- Davey Smith, G., & Pekkanen, J. (1992). Should there be a moratorium on the use of cholesterol lowering drugs? BMJ. https://doi.org/10.1136/bmj.304.6824.431
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.